First Time Loading...

Zymeworks Inc
NYSE:ZYME

Watchlist Manager
Zymeworks Inc Logo
Zymeworks Inc
NYSE:ZYME
Watchlist
Price: 9.09 USD -1.73%
Updated: Apr 16, 2024

Intrinsic Value

Zymeworks, Inc. is a clinical-stage biopharmaceutical company, engages in the discovery, development and commercialization of biotherapeutics. [ Read More ]

The intrinsic value of one ZYME stock under the Base Case scenario is 8.84 USD. Compared to the current market price of 9.09 USD, Zymeworks Inc is Overvalued by 3%.

Key Points:
ZYME Intrinsic Value
Base Case
8.84 USD
Overvaluation 3%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Zymeworks Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ZYME stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Zymeworks Inc

Provide an overview of the primary business activities
of Zymeworks Inc.

What unique competitive advantages
does Zymeworks Inc hold over its rivals?

What risks and challenges
does Zymeworks Inc face in the near future?

Has there been any significant insider trading activity
in Zymeworks Inc recently?

Summarize the latest earnings call
of Zymeworks Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Zymeworks Inc.

Provide P/S
for Zymeworks Inc.

Provide P/E
for Zymeworks Inc.

Provide P/OCF
for Zymeworks Inc.

Provide P/FCFE
for Zymeworks Inc.

Provide P/B
for Zymeworks Inc.

Provide EV/S
for Zymeworks Inc.

Provide EV/GP
for Zymeworks Inc.

Provide EV/EBITDA
for Zymeworks Inc.

Provide EV/EBIT
for Zymeworks Inc.

Provide EV/OCF
for Zymeworks Inc.

Provide EV/FCFF
for Zymeworks Inc.

Provide EV/IC
for Zymeworks Inc.

Show me price targets
for Zymeworks Inc made by professional analysts.

What are the Revenue projections
for Zymeworks Inc?

How accurate were the past Revenue estimates
for Zymeworks Inc?

What are the Net Income projections
for Zymeworks Inc?

How accurate were the past Net Income estimates
for Zymeworks Inc?

What are the EPS projections
for Zymeworks Inc?

How accurate were the past EPS estimates
for Zymeworks Inc?

What are the EBIT projections
for Zymeworks Inc?

How accurate were the past EBIT estimates
for Zymeworks Inc?

Compare the revenue forecasts
for Zymeworks Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Zymeworks Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Zymeworks Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Zymeworks Inc compared to its peers.

Compare the P/E ratios
of Zymeworks Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Zymeworks Inc with its peers.

Analyze the financial leverage
of Zymeworks Inc compared to its main competitors.

Show all profitability ratios
for Zymeworks Inc.

Provide ROE
for Zymeworks Inc.

Provide ROA
for Zymeworks Inc.

Provide ROIC
for Zymeworks Inc.

Provide ROCE
for Zymeworks Inc.

Provide Gross Margin
for Zymeworks Inc.

Provide Operating Margin
for Zymeworks Inc.

Provide Net Margin
for Zymeworks Inc.

Provide FCF Margin
for Zymeworks Inc.

Show all solvency ratios
for Zymeworks Inc.

Provide D/E Ratio
for Zymeworks Inc.

Provide D/A Ratio
for Zymeworks Inc.

Provide Interest Coverage Ratio
for Zymeworks Inc.

Provide Altman Z-Score Ratio
for Zymeworks Inc.

Provide Quick Ratio
for Zymeworks Inc.

Provide Current Ratio
for Zymeworks Inc.

Provide Cash Ratio
for Zymeworks Inc.

What is the historical Revenue growth
over the last 5 years for Zymeworks Inc?

What is the historical Net Income growth
over the last 5 years for Zymeworks Inc?

What is the current Free Cash Flow
of Zymeworks Inc?

AI Assistant can make mistakes. Consider checking important information.
Financials

Balance Sheet Decomposition
Zymeworks Inc

Current Assets 412.9m
Cash & Short-Term Investments 374.3m
Receivables 19.5m
Other Current Assets 19.1m
Non-Current Assets 168m
Long-Term Investments 82.1m
PP&E 37.5m
Intangibles 37.3m
Other Non-Current Assets 11m
Current Liabilities 55.8m
Accounts Payable 6.2m
Accrued Liabilities 40.8m
Other Current Liabilities 8.8m
Non-Current Liabilities 60.3m
Long-Term Debt 92k
Other Non-Current Liabilities 60.2m
Efficiency

Earnings Waterfall
Zymeworks Inc

Revenue
76m USD
Operating Expenses
-214.1m USD
Operating Income
-138.1m USD
Other Expenses
19.4m USD
Net Income
-118.7m USD

Free Cash Flow Analysis
Zymeworks Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ZYME Profitability Score
Profitability Due Diligence

Zymeworks Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROIC is Increasing
ROE is Increasing
Exceptional Revenue Growth Forecast
25/100
Profitability
Score

Zymeworks Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

ZYME Solvency Score
Solvency Due Diligence

Zymeworks Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
73/100
Solvency
Score

Zymeworks Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ZYME Price Targets Summary
Zymeworks Inc

Wall Street analysts forecast ZYME stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZYME is 14.93 USD with a low forecast of 10.1 USD and a high forecast of 22.05 USD.

Lowest
Price Target
10.1 USD
11% Upside
Average
Price Target
14.93 USD
64% Upside
Highest
Price Target
22.05 USD
143% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ZYME Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ZYME Price
Zymeworks Inc

1M 1M
-15%
6M 6M
+29%
1Y 1Y
-11%
3Y 3Y
-70%
5Y 5Y
-43%
10Y 10Y
-30%
Annual Price Range
9.09
52w Low
6.18
52w High
12.9
Price Metrics
Average Annual Return 20.37%
Standard Deviation of Annual Returns 123.16%
Max Drawdown -92%
Shares Statistics
Market Capitalization 643.3m USD
Shares Outstanding 70 570 000
Percentage of Shares Shorted 8.1%

ZYME Return Decomposition
Main factors of price return

What is price return decomposition?

ZYME News

Last Important Events
Zymeworks Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Zymeworks Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Zymeworks Inc Logo
Zymeworks Inc

Country

Canada

Industry

Biotechnology

Market Cap

643.3m USD

Dividend Yield

0%

Description

Zymeworks, Inc. is a clinical-stage biopharmaceutical company, engages in the discovery, development and commercialization of biotherapeutics. The company is headquartered in Vancouver, British Columbia and currently employs 458 full-time employees. The company went IPO on 2017-04-28. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. Its ZymeLink, which is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

Contact

BRITISH COLUMBIA
Vancouver
Suite 800 - 114 East 4Th Avenue
+16046781388.0
https://www.zymeworks.com/

IPO

2017-04-28

Employees

458

Officers

CEO & Chairman of the Board
Mr. Kenneth H. Galbraith C.A.
Senior VP & CFO
Dr. Christopher Astle Ph.D.
Chief Scientific Officer
Dr. Paul Moore Ph.D.
Executive VP and Head of Technical & Manufacturing Operations
Mr. Mark Hollywood
Senior VP, Corporate Secretary & General Counsel
Mr. Daniel Dex J.D., Ph.D.
Senior Manager of Corporate Communications
Diana Papove
Show More
Vice President of Corporate Development
Dr. Lindsey Foulkes B.Sc., Ph.D.
Vice President of Human Resources & DEI
Ms. Laura O'Connor
Executive VP & Chief Medical Officer
Dr. Jeffrey Smith M.D.
Managing Director of Early-Stage Development for Asia Pacific
Dr. Josemund Menezes MBBS
Show Less

See Also

Discover More
What is the Intrinsic Value of one ZYME stock?

The intrinsic value of one ZYME stock under the Base Case scenario is 8.84 USD.

Is ZYME stock undervalued or overvalued?

Compared to the current market price of 9.09 USD, Zymeworks Inc is Overvalued by 3%.